Sometimes a medical device company just needs the right combination of product approvals, market timing, and clearer vision to get Wall Street excited again. That's what happened Tuesday when William Blair upgraded Medtronic Plc (MDT), shifting from Market Perform to Outperform.

Analyst Brandon Vazquez explained that his previous Market Perform rating reflected a straightforward concern: Medtronic was too large and not differentiated enough to consistently deliver the high-single-digit EPS growth it kept promising. But things are changing. The company is ramping several new products, with many more waiting in the wings.

The Math That Makes This Interesting

Here's the investment thesis in simple terms. If Medtronic can actually achieve high-single-digit EPS growth, investors could see low-double-digit equity returns when you factor in the company's 2.9% dividend yield. That's pretty attractive.

"At a valuation of roughly 16 times calendar 2026 EPS, the stock is trading in line to slightly below large-cap medtech peers, suggesting a favorable risk/reward for an improving setup," Vazquez noted.

The stock was up 2.91% at $98.05 on Tuesday, suggesting investors found the argument compelling.

Hugo's Long Journey Finally Gets Somewhere

The Hugo surgical robot system has been nearly a decade in the making, and it finally has a more concrete timeline. The FDA recently approved it for urologic surgical procedures in the U.S., which could mark a turning point for Medtronic's surgical segment. That segment represented 19% of revenues in 2025 but has been growing slower than the company average over the past five years. A successful Hugo rollout could change that trajectory.

Meanwhile, the Symplicity Spyral RDN system for renal denervation hit a major commercialization milestone in late 2025 with final CMS national coverage. Management views the decision as more favorable than the draft version and sufficient to support broad patient access. William Blair expects a measured revenue ramp given the nuanced clinical evidence base, but CMS reimbursement dramatically improves visibility and allows RDN to start contributing meaningfully to the bottom line.

Pulsed Field Ablation and the Diabetes Spin

Pulsed Field Ablation remains one of Medtronic's fastest-growing businesses and helps offset slower growth in legacy pacing and defibrillation markets. The PFA platform strengthens the company's competitive position in atrial fibrillation by stabilizing market share with potential for modest gains, increasing exposure to a large and expanding AF ablation market as adoption rises, and delivering clear margin upside as volumes scale.

"We view the diabetes spin-off as compelling for both parties, allowing the newly formed MiniMed to focus on becoming a staple in the diabetes market and Medtronic to allocate resources toward the aforementioned growth drivers," Vazquez wrote in his investor note.

In other words, Medtronic is simplifying its focus and betting on products that actually have momentum. After years of being too big and too diversified to move the needle consistently, the company might finally have a clearer path forward.